We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

8 hedge funds and large institutions have $9.12K invested in Evofem Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,350% more call options, than puts

Call options by funds: $189K | Put options by funds: $2K

82% less funds holding

Funds holding: 44 → 8 (-36)

95% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 38

100% less capital invested

Capital invested by funds: $8.59M → $9.12K (-$8.58M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3

Holders
8
Holders Change
-36
Holders Change %
-81.82%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
3
Closed
38
Calls
$189K
Puts
$2K
Net Calls
+$187K
Net Calls Change
-$2.46M

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$27.7K
2
AWM
Activest Wealth Management
Florida
+$13.5K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$2.92M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$2.2M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$1.47M
4
Citigroup
Citigroup
New York
-$832K
5
BlackRock
BlackRock
New York
-$265K
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
1
Clear Street
New York
$5K +$27.7K +30,000 New
IA
2
IFP Advisors
Florida
$2K – – –
AWM
3
Activest Wealth Management
Florida
$2K +$13.5K +14,667 New
WIM
4
Westside Investment Management
California
$113 -$8.62K -9,334 -93%
LTI
5
Laffer Tengler Investments
Tennessee
$2 – – –
BBA
6
Baker Bros. Advisors
New York
– -$2.92M -2,583,616 Closed
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
– -$2.2M -1,950,607 Closed
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$1.47M -1,304,514 Closed
Citigroup
9
Citigroup
New York
– -$832K -736,406 Closed
BlackRock
10
BlackRock
New York
– -$265K -234,225 Closed
Citadel Advisors
11
Citadel Advisors
Florida
– -$238K -210,122 Closed
Geode Capital Management
12
Geode Capital Management
Massachusetts
– -$110K -97,953 Closed
FWSM
13
First Wilshire Securities Management
California
– -$83K -73,333 Closed
Morgan Stanley
14
Morgan Stanley
New York
– -$66K -58,882 Closed
Jane Street
15
Jane Street
New York
– -$64K -56,339 Closed
BRWA
16
B. Riley Wealth Advisors
Florida
– -$48K -42,108 Closed
Millennium Management
17
Millennium Management
New York
– -$42K -37,160 Closed
Simplex Trading
18
Simplex Trading
Illinois
– -$33.2K -35,957 -99%
SSA
19
Schonfeld Strategic Advisors
New York
– -$32K -28,100 Closed
SCA
20
Sassicaia Capital Advisers
New York
– -$31K -27,000 Closed
State Street
21
State Street
Massachusetts
– -$30K -26,200 Closed
Northern Trust
22
Northern Trust
Illinois
– -$21K -18,325 Closed
Mercer Global Advisors
23
Mercer Global Advisors
Colorado
– -$17K -15,001 Closed
Commonwealth Equity Services
24
Commonwealth Equity Services
Massachusetts
– -$12K -11,437 Closed
Creative Planning
25
Creative Planning
Kansas
– -$12K -10,356 Closed
1
2

EVFM Hedge Fund Activity: Q3 2022 in Review

8 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q3 2022, worth a combined $9.12K — down 100% from $8.59M a quarter earlier.

Sellers outnumbered buyers: 38 funds closed out of EVFM and 2 opened new positions — a net loss of 36 holders — while 3 trimmed existing stakes and 0 added.

The largest buyer was Clear Street, opening a new position worth an estimated $27.7K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $2.92M sold.

  • 8 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q3 2022, down from 44 in Q2 2022.
  • Funds reported $9.12K of Evofem Biosciences, Inc. Common Stock stock for Q3 2022, down 100% quarter-over-quarter.
  • 2 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q3 2022 and 38 closed out, a net change of -36 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q3 2022 was Clear Street, an estimated $27.7K added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q3 2022 was Baker Bros. Advisors, an estimated $2.92M sold.

Based on aggregated 13F filings for Q3 2022.